Along with being an active angel investor, I'm the ceo/founder of Nanotrace, a stealthmode biotech based in San Francisco. Backed by Kleiner Perkins, DCVC, and others, Nanotrace combined the best attributes of chemotherapy, nanoparticle delivery mechanisms, and the latest advancements in gene therapeutics. Based on our team's decades of research in these fields, and the maturation of nanomedicine, our product is a novel targeting platform which recognizes cancer cells by its very blueprint – gene expression. In part by using AI, that highly specific recognition is programmed to release a chemotherapeutic payload inside a cancer cell while leaving healthy cells unaffected. Our platform will transform how we treat not only cancer but a whole spectrum of genetic disorders.

Nanotrace is founded by David Spector; Dr. Will Briley; Dr. Paul Weiss, renowned nanoscientist and UCLA professor (wikipedia); Chief Medical Advisor, Dr. Krishna Komanduri, Dept Chief of Hematology & Oncology, UCSF.